Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan integrates Juvederm supplier

This article was originally published in The Gray Sheet

Executive Summary

Allergan will pay $216 mil. to acquire French firm Groupe Corneal Laboratoires - supplier of the firm's Juvederm next-generation hyaluronic acid dermal filler products - under a Nov. 1 agreement. Allergan, which previously held exclusive marketing rights to Juvederm and future product line extensions in the U.S., Canada and Australia, now gains exclusive rights to the technology worldwide. The deal also gives the firm control over future development and manufacturing of Juvederm and related hyaluronic acid dermal fillers. Allergan gained its initial rights to the injectable facial wrinkle treatment via its March purchase of aesthetic device maker Inamed and plans a January 2007 launch following FDA approval in June (1"The Gray Sheet" June 12, 2006, p. 15). The GCL deal is expected to close in the first quarter of 2007. Drug and device maker Allergan reported Q3 device sales of $116.3 mil. - all from Inamed - representing 15% of its $791.7 mil, in corporate sales...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT024146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel